American Vanguard Corp: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 9, 2020 and accepted by EDGAR at Nov 9, 2020, 16:36 ET.
Management's discussion and analysis
As filed, 39,438 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD-LOOKING STATEMENTS/RISK FACTORS:
The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
MANAGEMENT OVERVIEW
The Company’s Operations in the Context of the COVID-19 Pandemic
In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic, and it continues to spread across the world. To limit the spread of the contagion, governments have taken various actions to slow and otherwise control the spread of the pandemic, including the issuance of stay-at-home orders, social distancing guidelines and border restrictions. At its outset, the Company took swift action to understand, contain and mitigate the risks posed by this pandemic. Specifically, we formed the Pandemic Work Group with a mission to ensure the health and safety of the workforce while ensuring continuity of the business. In the workplace, we have designed and implemented protocols for social distancing, made provisions for the workforce to work remotely where possible, and established quarantine policies for those who present COVID-like symptom or may have been in touch with those who have. Further, the group keeps current with local, state, federal and international laws and restrictions that could affect the business; provides real-time information to the workforce; and draws from political commentary and news statements concrete directions on how best to continue operations. We have also prepared contingency plans to permit the continued operation of our factories, in the event that there are critical staffing issues due to attrition. In addition, in April 2020, we amended our credit facility to support future working capital needs. Further, we continuously monitor supply chain, transport, logistics and border closures and have reached out to third parties to make clear that we are continuing to operate, that we have our own policies relating to health and are committed to compliance with COVID-19 policies of our business partners. Our Chief Executive Officer and the Pandemic Work Group are holding regular “state of the company” calls with the functional heads of our businesses across the globe to ensure that our information is shared in a timely manner and that our direction is clear.
It is important to understand that under applicable federal guidelines (at https://www.cisa.gov), the Company is part of the nation’s “critical infrastructure” and falls within three of the 16 sectors that are specially permitted to operate: “Food and Agriculture” sector (engaged in “the production of chemicals and other substances used by the food and agriculture industry, including pesticides, herbicides etc.”), the “Chemical” sector (supporting the operation . . . of facilities (particularly those with high risk chemicals . . . whose work cannot be done remotely and requires the presence of highly trained personnel to ensure safe operations”) and the “Public Works and Infrastructure Support Services” sector (in support of public health including pest control and exterminators, landscapers and others who provide services to residences and businesses). In issuing guidance on Coronavirus, President Trump said, “If you work in a critical infrastructure industry, as defined by the Department of Homeland Security, such as healthcare services and pharmaceutical and food supply, you have a special responsibility to maintain your normal work schedule [emphasis added].” We have found that state COVID-19 orders and, indeed, even those of countries in which the outbreak has been most pronounced, have consistently excepted food supply as an area essential to the survival of its populations and, as such, had given special permission to companies, such as ours, to continue to operate during the pandemic even during strict lockdowns.
In keeping with our charge to operate as an essential business and by virtue of our efforts to contain and mitigate the risks posed by the pandemic, we have been able to manage our business with minimal disruption during the reporting period. As mentioned earlier (see Note 1 to the Condensed Consolidated Financial Statements), the coronavirus has affected our overall performance to a degree. Lost opportunities for certain new product launches, inability to meet potential new customers face-to-face, reduced demand for commodity crops sold to restaurants, and foreign exchange effects in Brazil, Mexico and Australia, have likely limited the Company’s top-line growth by up to several million dollars and the associated profitability, to an indeterminate degree, since the inception of the pandemic.
Overview of the Company’s Third Quarter 2020 Performance ended September 30, 2020
The Company’s quarterly performance was, on the whole, about even with that of the comparable quarter in 2019. While sales declined by about 6% (to $117,439 in 2020 from $124,884 in 2019), net income was about even ($2,927 in 2020 v. $3,153 in 2019). As described in more detail below, domestic sales declined by about 10% due in part to severe weather conditions, commodity prices and conservative procurement practices amidst the pandemic. By contrast, international sales were flat quarter-over-quarter. Within that performance, Mexico, Central America and Australia all grew sales compared to the prior year. Overall cost of sales were slightly higher as a percentage of net sales, including a factory performance that was approximately flat compared to the same three-months period of 2019, and gross profit declined by 9% ($43,265 v. $47,463). Consequently, gross margin percentage decreased to 37% from 38% of net sales. Operating expenses decreased by about 5% (to $38,782 in 2020 from $40,677 in 2019), but remained flat at about 33% of net sales. With a lower base interest rate and more aggressive repayment of debt, our interest expense decreased by about 50%. Also, due to a higher mix of business in lower-tax jurisdictions coupled with two favorable adjustments, we benefitted from a lower effective tax rate. This yielded net income for the quarter in line with the same quarter of 2019. In short, the Company was able to maintain profitability on an absolute basis, despite a reduced top line in the midst of a global pandemic.
Details on our financial performance are set forth below.
RESULTS OF OPERATIONS
Quarter Ended September 30, 2020 and 2019:
| Net sales: | 2020 | 2019 | Change | % Change |
|---|---|---|---|---|
| US crop | $48,361 | $55,072 | $(6,711) | -12% |
| US non-crop | 18,251 | 18,995 | (744) | -4% |
| Total US | 66,612 | 74,067 | (7,455) | -10% |
| International | 50,827 | 50,817 | 10 | 0% |
| Total net sales | $117,439 | $124,884 | $(7,445) | -6% |
| Cost of sales: | ||||
| US crop | $28,215 | $31,362 | $(3,147) | -10% |
| US non-crop | 9,493 | 9,135 | 358 | 4% |
| Total US | 37,708 | 40,497 | (2,789) | -7% |
| International | 36,466 | 36,924 | (458) | -1% |
| Total cost of sales | $74,174 | $77,421 | $(3,247) | -4% |
| Gross profit: | ||||
| US crop | $20,146 | $23,710 | $(3,564) | -15% |
| US non-crop | 8,758 | 9,860 | (1,102) | -11% |
| Total US | 28,904 | 33,570 | (4,666) | -14% |
| International | 14,361 | 13,893 | 468 | 3% |
| Total gross profit | $43,265 | $47,463 | $(4,198) | -9% |
| Gross margin: | ||||
| US crop | 42% | 43% | ||
| US non-crop | 48% | 52% | ||
| Total US | 43% | 45% | ||
| International | 28% | 27% | ||
| Total gross margin | 37% | 38% |
Our domestic crop business recorded net sales that were about 12% lower than those of the prior year period ($48,361 v. $55,072). During the third quarter of 2020, the distribution channel continued conservative procurement practices due, among other things, to reduced ethanol demand, commodity pricing, a strained farm economy and the COVID-19 pandemic. This procurement pattern was particularly evident in Midwest corn and soybean markets. In cotton, net sales of our foliar insecticide Bidrin were lower this year due to multiple factors. First, low cotton commodity prices caused an 11% decline in planted cotton acres (down 1.5 million acres to 12.2 million). Second, unfavorable weather conditions, specifically extensive drought in West Texas and three successive hurricanes in the Southeast region, reduced product application. Similarly, our cotton harvest defoliant Folex generated lower third quarter sales following multiple hurricanes that struck the region late in the season, thereby destroying some harvestable acreage and otherwise delaying some harvesting applications to the fourth quarter. Offsetting some of these negative factors, we saw a strong performance in our soil fumigant business driven by a rebound in usage by potato growers as pandemic impacted restaurants and schools began to reopen.
Cost of sales within the domestic crop business was 10% lower than the third quarter of 2019 (down to $28,215 from $31,362) and gross margin decreased to 42% of sales during the third quarter as compared to 43% for the comparable period last year.
Sales of our domestic non-crop business were down about 4% ($18,251 from $18,995) quarter-over-quarter. Our Dibrom® mosquito adulticide sales, which constitute a significant portion of overall non-crop sales, were approximately flat as compared to the third quarter of the prior year, as the mosquito control distributors continued to work down channel inventory during a succession of tropical storms and hurricanes this season. Net sales of Pest Strip were down as a result of reduced demand from restaurants and other similar establishments, which were subject to pandemic restrictions. Net sales from our OHP nursery and ornamental business were slightly higher than last year, as demand for homeowner garden and landscape products remained stable at retail locations around the country. We continue to maintain a steady level of business with our other commercial pest control products.
Cost of sales within the domestic non-crop business increased by about 4% (from $9,135 to $9,493) quarter-over-quarter. Gross profit for domestic non-crop decreased by 11% (from $9,860 in 2019 to $8,758 in 2020); and gross margin percentage for the non-crop business declined to 48% for the quarter as compared to 52% during the third quarter of 2019.
Net sales of our international businesses were flat during the period ($50,827 in 2020 v. $50,817 in 2019). Several factors contributed to this result. Sales performance rose about 4% in Mexico and Central America on strong product demand for granular insecticides, bromacil herbicides and soil fumigants. In Brazil, net sales declined primarily as a result of the devaluation of the Brazilian Real in comparison to last year, which impacted sales when translated to US Dollars for inclusion in the financial statements. In addition, the business was impacted by limited customer access (in light of coronavirus protocols), competitive market conditions and the exchange rate impact when sales were translated from a local currency. In Europe, sales of our Mocap® insecticide declined due to the regulatory phase-out of that product, offset somewhat by increased demand in other countries. Overall our sales of Nemacur soil insecticide rose nearly 50% in the quarter, including lower sales in Europe primarily associated with timing on orders from our Italian commission agent that was more than offset by a threefold increase in sales to various other countries. The Nemacur performance more than offset the decline in Mocap. In Australia, third quarter sales doubled versus the prior year.
Cost of sales in our international business decreased slightly (about 1%) from $36,924 in 2019 to $36,466 in 2020. Gross profit for International rose by approximately 3% from $13,893 in 2019 to $14,361 in 2020, and gross margin improved from 27% in the third quarter of 2019 to 28% for the same period this year.
On a consolidated basis, gross profit for the quarter decreased by 9% (from $47,463 in 2019 to $43,265 in 2020). Gross margin percentage declined to 37% in the quarter, as compared to 38% in the same quarter of the prior year.
Operating expenses decreased by $1,895 to $38,782 for the three-months ended September 30, 2020, as compared to the same period in 2019. The differences in operating expenses by department are as follows:
| 2020 | 2019 | Change | % Change | |
|---|---|---|---|---|
| Selling | $10,824 | $11,961 | $(1,137) | -10% |
| General and administrative | 10,372 | 13,406 | (3,034) | -23% |
| Research, product development and regulatory | 6,639 | 5,417 | 1,222 | 23% |
| Freight, delivery and warehousing | 10,947 | 9,893 | 1,054 | 11% |
| $38,782 | $40,677 | $(1,895) | -5% |
- Selling expenses decreased by $1,137 to end at $10,824 for the three-months ended September 30, 2020, as compared to the same period of the prior year. The main drivers were the reduction in advertising and promotion costs, the favorable impact of lower foreign currency exchange rates (as they relate to operating expenses of certain foreign subsidiaries) and decreased travel and entertainment expenses across all of our global operating subsidiaries, as a result of restrictions imposed in response to the COVID-19 pandemic.
- General and administrative expenses decreased by $3,034 to end at $10,372 for the three-months ended September 30, 2020, as compared to the same period of 2019. The main drivers were the reduction in travel and entertainment expenses, legal expense and long-term incentive compensation. Further, we reduced our reserves for potential environmental expenses in the amount of $1,050, following the finalization of an updated environmental risk assessment related to the Brazilian businesses acquired in early 2019.
- Research, product development costs and regulatory expenses increased by $1,222 to end at $6,639 for the three-months ended September 30, 2020, as compared to the same period of 2019. The main drivers were increases in our product defense and development activities and business development associated with our SIMPAS proprietary packaging. These costs were partially offset by general delays of activities with third party service providers caused by pandemic-related disruption.
- Freight, delivery and warehousing costs for the three-months ended September 30, 2020 were $10,947 or 9.3% of sales as compared to $9,893 or 7.8% of sales for the same period in 2019. This change in cost was primarily driven by the overall mix of product sales recorded in 2020, as compared to the same period of the prior year.
Interest costs net of capitalized interest were $1,022 during the three-months ended September 30, 2020, as compared to $2,070 in the same period of 2019. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Three-months ended September 30, 2020 Average Debt | Interest Expense | Interest Rate | Three-months ended September 30, 2019 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $162,734 | $1,007 | 2.5% | $178,886 | $2,045 | 4.6% |
| Amortization of deferred loan fees | — | 80 | — | — | 58 | — |
| Amortization of other deferred liabilities | — | 2 | — | — | 41 | — |
| Other interest expense | — | 7 | — | — | 32 | — |
| Subtotal | 162,734 | 1,096 | 2.7% | 178,886 | 2,176 | 4.9% |
| Capitalized interest | — | (74) | — | — | (106) | — |
| Total | $162,734 | $1,022 | 2.5% | $178,886 | $2,070 | 4.6% |
The Company’s average overall debt for the three-months ended September 30, 2020 was $162,734, as compared to $178,886 for the three-months ended September 30, 2019. During the quarter, we continued to focus on managing our working capital for our expanded business and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.5% for the three-months ended September 30, 2020, as compared to 4.6% in 2019. The lower interest cost was substantially due to lower interest rates on borrowings in the US, which was part of Federal Government efforts to stimulate the overall economy.
Income tax expense was $492 for the three-months ended September 30, 2020, as compared to $1,474 for the comparable period in 2019. The effective tax rate for the quarter was 14.2%, as compared to 31.3% in the same period of the prior year. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The decrease in effective tax rate is primarily driven by the mix of our domestic and international income and the discrete benefit of the vesting of stock grants and the release of an uncertain tax position.
During the three-months ended September 30, 2020 and 2019, we recognized losses of $42 and $89, respectively, on our investment in the Hong Kong joint venture, which is a 50% owned equity investment.
Our overall net income for the three-months ended September 30, 2020 was $2,927 or $0.10 per basic and diluted share, as compared to $3,153 or $0.11 per basic and diluted share in the same period of 2019.
Overview of the Company’s Nine-Months Performance ended September 30, 2020
With the advent of the global pandemic early in the year, the Company’s performance during the first nine months of 2020 declined in most respects as compared to the same period in 2019. Our domestic non-crop sales were hampered by severe weather, commodity pricing, conservative procurement within the distribution channel and reduced acres of certain crops, such as cotton. By contrast, soil fumigants and new product introductions were strong. Similarly, non-crop sales declined due largely to lower sales of Dibrom as distribution worked down inventory levels; this decline was partially offset by higher royalties from our Envance essential oil products. On the international side, we experienced a modest overall decrease in sales, largely due to the phase-out of Mocap in the European Union (“EU”), market conditions in Brazil and pandemic restrictions in Central America. This was partially offset by strong performance in Mexico.
On a consolidated basis, with domestic sales down 7% and international sales down by about 4%, overall net sales were down by about 6% ($317,956 v. $337,664). Cost of sales were down 5% on an absolute basis, while, in part driven by a strong factory performance, which improved during the first nine months of 2020 as compared to that of 2019. These factors, taken together, yielded a decline in gross profit of 7% ($8,866). In the first three quarters of 2020 operating expenses reduced by about 2% on an absolute basis, with considerably lower sales and marketing expenditures due largely to reduced travel and entertainment activities and customer visit limitations caused by restrictions in place related to the pandemic. However, operating expenses as a percent of net sales rose from 33% to 34% for the period. After both significantly lower interest and tax expense in the 2020 reporting period, net income declined to $7,334 (or $0.25 per diluted share from $10,165 or $0.34 per diluted share) during the first three quarters of the prior year. Details on our financial performance are set forth below.
RESULTS OF OPERATIONS
Nine-months ended September 30, 2020 and 2019
| Net sales: | 2020 | 2019 | Change | % Change |
|---|---|---|---|---|
| US crop | $148,630 | $158,068 | $(9,438) | -6% |
| US non-crop | 37,881 | 42,068 | (4,187) | -10% |
| Total US | 186,511 | 200,136 | (13,625) | -7% |
| International | 131,445 | 137,528 | (6,083) | -4% |
| Total net sales | $317,956 | $337,664 | $(19,708) | -6% |
| Cost of sales: | ||||
| US crop | $80,511 | $89,009 | $(8,498) | -10% |
| US non-crop | 19,346 | 20,624 | (1,278) | -6% |
| Total US | 99,857 | 109,633 | (9,776) | -9% |
| International | 96,147 | 97,213 | (1,066) | -1% |
| Total cost of sales | $196,004 | $206,846 | $(10,842) | -5% |
| Gross profit: | ||||
| US crop | $68,119 | $69,059 | $(940) | -1% |
| US non-crop | 18,535 | 21,444 | (2,909) | -14% |
| Total US | 86,654 | 90,503 | (3,849) | -4% |
| International | 35,298 | 40,315 | (5,017) | -12% |
| Total gross profit | $121,952 | $130,818 | $(8,866) | -7% |
| Gross margin: | ||||
| US crop | 46% | 44% | ||
| US non-crop | 49% | 51% | ||
| Total US | 46% | 45% | ||
| International | 27% | 29% | ||
| Total gross margin | 38% | 39% |
Our domestic crop business recorded net sales that were about 6% below those of first three quarters of 2019 ($148,630 v. $158,068). When viewed by type of product and crop, sales were mixed. During the first nine months, we have seen careful procurement patterns in the domestic market, as low crop commodity prices and concerns about near-term demand from Asia caused growers and retailers to purchase crop protection inputs at a cautious and deliberate pace. With respect to our corn products, net sales of corn soil insecticides, including Aztec®, SmartChoice® and Counter®, and our Impact® post-emergent herbicide were lower as a result of this conservative approach to procurement. Also, a significant decline in planted cotton acres (relating to lower commodity prices) and unfavorable weather contributed to a drop in net sales of both our Bidrin® foliar insecticide product and our Folex® growth regulator. Partially offsetting these declines, soil fumigants had a strong performance during the first nine months of 2020 due to drier weather conditions in California and the Pacific Northwest, which facilitated more widespread product application largely on potato crops. Recently acquired products, including our rice herbicide Arroz®, our soybean herbicides (FirstRate, Classic and Python) and our miticide Stifle, provided a strong incremental upside during the first three quarters of 2020.
Cost of sales within the domestic crop business declined 9%, as compared to the first nine-months of 2019, and gross profit declined by 1% ($68,119 in 2020 versus $69,059 in 2019).
Our domestic non-crop business recorded a decrease in net sales (down about 10% to $37,881 from $42,068) versus the first three quarters of 2019. In this category, our Dibrom® mosquito adulticide sales declined significantly, as relatively full channel inventories were used to address the aftermath of a series of tropical storms and hurricanes in 2020. Royalty fees for our Envance essential oil technology were higher than the first nine months of last year; and we expect to recognize additional license fees and royalties during the balance of 2020. Net sales of Pest Strip were down as a result of reduced demand from restaurants and other similar establishments, which were subject to pandemic restrictions. Our OHP nursery and ornamental business posted an 8% sales increase, as demand for homeowner garden and landscape products continued unabated as consumers took increasingly to home improvement and gardening in light of pandemic restrictions.
Cost of sales within the domestic non-crop business decreased by about 6% (to $19,346 from $20,624) during the first nine-months of 2020 versus the comparable period in 2019. Gross profit for domestic non-crop decreased by 14% (to $18,535 in 2020 from $21,444 in 2019) due primarily to lower sales of our Dibrom mosquito adulticide.
Net sales of our international businesses were down by about 4% during the period ($131,445 in 2020 v. $137,528 in 2019). Several factors contributed to this result. In Europe, sales of our Mocap® insecticide continue to decline during the phase-out of that product following the cancellation of its registration in the EU. In Canada, we experienced a sharp decline in Assure II sales as a result of intense third quarter price competition; the Company elected to maintain brand value rather than match the downward price trend. Mexico posted improved sales with continuing demand for granular insecticides, bromacil herbicides, and soil fumigants for use on high-value vegetable crops. In Brazil, net sales declined due to lower disease pressure in soybeans (reducing demand for our fungicide products), portfolio streamlining and delays in procurement arising from uncertainty relating to the economy. The performances of our Brazilian and Mexican businesses were further affected by a devaluation in the Brazilian real and the Mexican peso. The average exchange rate of the Brazilian real and the Mexican peso decreased by approximately 23% and 11% for the nine-month period ended September 30, 2020 compared to the same period in the prior year.
Cost of sales in our international business decreased by 1% (from $97,213 in 2019 to $96,147 in 2020) primarily driven by mix and currency changes. Gross profit for the international businesses dropped by about 12% (from $40,315 in 2019 to $35,298 in 2020). This resulted from reduced sales of certain high margin products, including Mocap insecticide and Assure II herbicide. In addition, we experienced higher sales of lower-margin products from our business in Australia.
On a consolidated basis, gross profit for the nine-months of 2020 decreased by 7% (from $130,818 in 2019 to $121,952 in 2020), as a result of reduced sales volumes detailed above. Factory performance was significantly better in the first nine-months of 2020, as compared to the same period of 2019. Gross margin performance, when expressed as a percentage of sales, declined slightly to 38% from 39% in the comparable period of 2019.
Operating expenses decreased by $1,957 to $108,882 for the nine-months ended September 30, 2020, but were 34% of net sales, as compared with 33% of net sales during the same period in 2019. The differences in operating expenses by department are as follows:
| 2020 | 2019 | Change | % Change | |
|---|---|---|---|---|
| Selling | $31,329 | $34,646 | $(3,317) | -10% |
| General and administrative | 33,368 | 33,890 | (522) | -2% |
| Research, product development and regulatory | 18,896 | 17,956 | 940 | 5% |
| Freight, delivery and warehousing | 25,289 | 24,347 | 942 | 4% |
| $108,882 | $110,839 | $(1,957) | -2% |
- Selling expenses decreased by $3,317 to end at $31,329 for the nine-months ended September 30, 2020, as compared to the same period of 2019. The main drivers were the reduction in advertising and promotion costs, the favorable impact of lower foreign currency exchange rates (as they relate to the translation of operating expenses of certain foreign subsidiaries) and decreased travel and entertainment activities across our global operating subsidiaries, as a result of restrictions imposed in response to the COVID-19 pandemic.
- General and administrative expenses decreased by $522 to end at $33,368 for the nine-months ended September 30, 2020, as compared to the same period of 2019. The main drivers for the decrease were associated with the reduction in travel and entertainment expenses in response to the COVID-19 pandemic, a reduction in environmental reserves associated with our Brazilian business, lower legal expenses and incentive compensation. These categories of expenses were comparatively higher in the same period of 2019; however, due to two adjustments amounting to $3,539 in 2019 (an adjustment made to the fair value of the acquisition related to the deferred consideration liabilities and a break-up fee arising from an unconsummated acquisition) the overall expense for the comparative periods was nearly flat.
- Research, product development costs and regulatory expenses increased by $940 to end at $18,896 for the nine-months ended September 30, 2020, as compared to the same period of 2019. The main drivers were increases in our product defense and product development costs, primarily resulting from increase activities in our newly acquired businesses in 2019, partially offset by the general delays in activities with third party service providers caused by pandemic related disruption.
- Freight, delivery and warehousing costs for the nine-months ended September 30, 2020 were $25,289 or 8.0% of sales as compared to $24,347 or 7.2% of sales for the same period in 2019. This change in cost was primarily driven by the overall mix of product sales recorded in 2020, as compared to the same period of the prior year.
Interest costs net of capitalized interest were $3,804 in the first nine-months of 2020, as compared to $5,606 in the same period of 2019. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Nine-months ended September 30, 2020 Average Debt | Interest Expense | Interest Rate | Nine-months ended September 30, 2019 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $171,203 | $3,751 | 2.9% | $166,877 | $5,530 | 4.4% |
| Amortization of deferred loan fees | — | 219 | — | — | 161 | — |
| Amortization of other deferred liabilities | — | 8 | — | — | 41 | — |
| Other interest expense | — | 64 | — | — | 102 | — |
| Subtotal | 171,203 | 4,042 | 3.1% | 166,877 | 5,834 | 4.7% |
| Capitalized interest | — | (238) | — | — | (228) | — |
| Total | $171,203 | $3,804 | 3.0% | $166,877 | $5,606 | 4.5% |
The Company’s average overall debt for the nine-months ended September 30, 2020 was $171,203, as compared to $166,877 for the nine-months ended September 30, 2019. During the period, we continued to focus on our usage of revolving debt, while funding working capital for the newly acquired products and businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.9% for the nine-months ended September 30, 2020, as compared to 4.4% in 2019.
Income tax expense decreased by $2,207 to end at $1,852 for the nine-months ended September 30, 2020, as compared to income tax expense of $4,059 for the comparable period in 2019. The effective tax rate for the nine-months ended September 30, 2020 was 20.0%, which included three discrete income tax benefits during the nine-months ended September 30, 2020. First, the Company assessed its income tax positions to account for the Coronavirus Aid Relief and Economic Security Act (“CARES Act”) which was signed into law on March 27, 2020. A provision of the act modified the amount of interest deduction allowed and therefore reduced the Company’s 2019 Global Intangible Low Tax Income (“GILTI”) inclusion. Second, the Company benefited from the tax impact of the vesting of certain stock grants. Third, the Company benefited from the release of an uncertain tax position. During the nine-months ended September 30, 2019, the Company’s effective tax rate was 28.2%. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.
During the nine-months ended September 30, 2020 and 2019, the Company recognized losses of $80 and $149, respectively, on its investment in the Hong Kong joint venture which is a 50% owned equity investment.
Our overall net income for the nine-months ended September 30, 2020 was $7,334 or $0.25 per basic and diluted share, as compared to $10,165 or $0.35 per basic and $0.34 per diluted share in the same period of 2019.
LIQUIDITY AND CAPITAL RESOURCES
The Company’s operating activities provided net cash of $19,197 during the nine-months ended September 30, 2020, as compared to utilizing $21,053 during the nine-months ended September 30, 2019. Included in the $19,197 are net income of $7,334, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $14,584, the amortization of other assets of $3,185 and provision for bad debts in the amount of $777. Also included are stock-based compensation of $3,776, change in investment fair value of $281, loss from equity method investment of $80, decrease in deferred income taxes of $1,757 and net foreign currency adjustment of $711. These together provided net cash inflows of $26,996, as compared to $29,860 for the same period of 2019.
During the nine-months of 2020, the Company increased working capital by $4,950, as compared to an increase of $49,160 during the same period of the prior year. Included in this change: inventories increased by $16,941, as compared to $19,713 for the nine-months of 2019. Deferred revenue decreased by $1,079, as compared to $19,800 in the same period of 2019, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances decreased by $1,759, as compared to $5,548 in the same period of 2019. Accounts receivables increased by $5,089, as compared to $15,839 in the same period of 2019. Prepaid expenses increased by $532, as compared to $849 in the same period of 2019. Income tax receivable net decreased by $873, as compared to an increase by $4,477 in the prior year. Accrued programs increased by $20,058, as compared to $20,163 in the prior year. The change reflected some changes in product mix and domestic programs. Finally, other payables and accrued expenses decreased by $3,344, as compared to $4,967 in the prior year as a result of the reduced incentive compensation accrual.
With regard to our program accrual, the increase (as noted above) primarily reflects our mix of sales and customers in the first nine-months of 2020, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first nine-months of 2020, the Company made accruals for programs in the amount of $42,254 and made payments in the amount of $22,208. During the first nine-months of the prior year, the Company made accruals in the amount of $37,903 and made payments in the amount of $17,740.
Cash used for investing activities was $14,120 for the nine-months ended September 30, 2020, as compared to $42,382 for the nine-months ended September 30, 2019. The Company spent $8,988 on fixed assets acquisitions, primarily focused on continuing to invest in manufacturing infrastructure, and $5,132 on investments and intangible assets.
During the nine-months ended September 30, 2020, financing activities used $1,855, as compared to provide $63,825 for the same period of the prior year. This is principally from the reduced borrowings on the Company’s senior credit facility. In the first nine-months of 2020, the Company paid dividends to stockholders amounting to $1,168, as compared to $1,741 in the same period of 2019.
The Company has a revolving line of credit that is shown as long-term debt in the Condensed Consolidated Balance Sheets at September 30, 2020 and December 31, 2019. These are summarized in the following table:
| Long-term indebtedness ($000's) | September 30, 2020 | December 31, 2019 |
|---|---|---|
| Revolving line of credit | $149,900 | $149,300 |
| Deferred loan fees | (538) | (534) |
| Net long-term debt | $149,362 | $148,766 |
At September 30, 2020, the Company is compliant with all covenants to its Senior Credit Facility. Based on its performance against the most restrictive covenants in the Credit Agreement (see, supra Note 10), the Company had the capacity to increase its borrowings by up to $44,500, according to the terms thereof. This compares to an available borrowing capacity of $30,435 as of September 30, 2019 and $26,977 at December 31, 2019. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve month period and on a proforma basis arising from acquisitions, (2) net borrowings, (3) the leverage covenant (the Consolidated Funded Debt Ratio).
We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.
RECENTLY ISSUED ACCOUNTING GUIDANCE
Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2019, except for the adoption of Accounting Standards Update (“ASU”) 2016-13, “Financial Instruments – Credit Losses (Topic 326)”, along with related clarifications and improvements.
Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the Condensed Consolidated Financial Statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.
Market risk
As filed, 1,173 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2019.
The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.
Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.
Controls and procedures
As filed, 1,066 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of September 30, 2020, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of September 30, 2020, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.
PART II. OTHER INFORMATION
The Company was not required to report any matters or changes for any items of Part II except as disclosed below.
Risk factors
As filed, 2,102 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2019, filed on March 10, 2020. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors, except for the following:
The Covid-19 pandemic is creating risk, uncertainty and adverse conditions in many industries both here and abroad. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic has impacted and may, in the future, impact its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the three- and nine-months ended September 30, 2020, the coronavirus did have the effect of limiting sales on new product launches, limiting interactions with potential new customers, reducing demand for products used on crops that are purchased by restaurants, and negatively impacting foreign currency exchange rates in Brazil, Mexico and Australia. The Company is unable to predict the impact that the pandemic will have on its financial condition, results of operations and cash flows in future reporting due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations will not be materially adversely affected by the pandemic in future quarters.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $117.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $318.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $74.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $196.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $43.3m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $122.0m | us-gaap:GrossProfit |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $4.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $13.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $1.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $3.8m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $492.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $1.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $2.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $7.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $0.10 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 29,973,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 29,926,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $19.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 9 months2020-01-01 to 2020-09-30 | $1.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2020-09-30 | $9.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $353.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $675.7m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $150.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $330.9m | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $149.4m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2020-09-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2020-09-30 | $344.8m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001564590-20-052550. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.